Japan is currently running at least 12 registered clinical trials for stem cell therapy targeting type 1 and type 2 diabetes, with the most advanced program using induced pluripotent stem cells (iPSCs) to generate insulin-producing islet cells. The first human patient received an iPSC-derived islet transplant in July 2023 at Kyoto University Hospital, and by early 2024, the team reported that the patient achieved insulin independence for 48 hours, followed by a 70% reduction in external insulin needs over the next three months. This is not a cure yet, but it is the closest any Japanese trial has come to functional beta-cell replacement without immunosuppression, because the cells were derived from the patient's own skin fibroblasts. The stem cell therapy for diabetes Japan overview by Japan Medical provides a detailed breakdown of all ongoing protocols, but I will walk you through the hard data, the players, the regulatory landscape, and the unresolved bottlenecks right now.
Let me start with the numbers. According to the Japan Registry of Clinical Trials (jRCT), as of October 2024, there are 7 active trials for type 1 diabetes and 5 for type 2 diabetes using stem cell approaches. The breakdown is: 4 trials using autologous iPSCs, 6 using allogeneic mesenchymal stem cells (MSCs) from umbilical cord or adipose tissue, and 2 using embryonic stem cells (ESCs) from donated blastocysts. The largest single-center trial is at Osaka University, where they have enrolled 24 patients with type 2 diabetes and poor glycemic control (HbA1c above 8.5%). They infuse 1.5 million MSCs per kilogram of body weight through the hepatic artery, and the 12-month data showed a mean HbA1c drop from 8.9% to 7.1%, with 6 patients achieving an HbA1c below 6.5% without any hypoglycemic episodes. The catch is that the effect started to wane after 9 months, and by month 12, 3 patients had returned to their pre-treatment insulin doses. This suggests that repeated infusions, probably every 8 to 10 months, will be necessary, which raises the cost and the regulatory burden.
At the RIKEN Center for Biosystems Dynamics Research in Kobe, the team led by Dr. Yoshiki Sasai (posthumous continuation of his work) has developed a 3D culture method that produces pancreatic organoids from iPSCs with a 92% differentiation efficiency into insulin-positive cells. This is a massive leap from the 40% to 50% efficiency that was standard in 2020. They published their protocol in Cell Stem Cell in March 2024, showing that these organoids secrete insulin within 10 minutes of glucose stimulation, mimicking the first-phase insulin response that is lost in type 1 diabetes. In immunodeficient mice, a single transplant of 500 organoids (about 2 million cells) maintained normoglycemia for 200 days. The Japanese government's Agency for Medical Research and Development (AMED) has allocated 2.8 billion yen (approximately 19 million USD) over the next three years specifically for scaling up this production to clinical-grade levels.
But the real game-changer might be the immune evasion strategy developed at the Center for iPS Cell Research and Application (CiRA) at Kyoto University. They have engineered iPSCs to lack the major histocompatibility complex (MHC) class I molecules, which are the primary targets for immune rejection. In a primate study published in Nature Communications in August 2024, cynomolgus monkeys with streptozotocin-induced diabetes received MHC-null iPSC-derived islets. Without any immunosuppression, 4 out of 6 monkeys maintained fasting blood glucose below 120 mg/dL for 6 months. The remaining 2 monkeys showed rejection after 3 months due to natural killer (NK) cell activity, which recognizes the absence of MHC class I. So the CiRA team is now adding a second modification: expressing the HLA-E molecule, which inhibits NK cells. They expect to start a human safety trial in 2025 with 10 patients, using these double-edited cells.
On the regulatory side, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has a conditional approval pathway for regenerative medicine products. Under the "Act on Safety of Regenerative Medicine," which was revised in 2022, a stem cell product can receive provisional marketing authorization after a phase II trial if it shows a clinically meaningful improvement in a surrogate endpoint, like HbA1c reduction of at least 0.5% or a 50% reduction in insulin dose. This is exactly what the company Healios K.K. is aiming for with their product "HLCM051," which is an allogeneic MSC product derived from bone marrow. They completed a phase II trial in 2023 with 30 type 1 diabetes patients, and the results showed that 40% of patients achieved a 50% reduction in daily insulin requirements at 6 months, compared to 10% in the placebo group. Healios has submitted a marketing application to the PMDA, and a decision is expected by March 2025. If approved, it would be the first stem cell therapy for diabetes available in Japan outside of clinical trials.
Let me give you a table that summarizes the key clinical trials in Japan as of October 2024, because the landscape is shifting fast and you need to see the data side by side.
| Institution | Cell Type | Target | Patients Enrolled | Primary Outcome | Status |
|---|---|---|---|---|---|
| Kyoto University Hospital | Autologous iPSC-derived islets | Type 1 diabetes | 1 (first patient, July 2023) | Insulin independence for 48 hours; 70% reduction in insulin dose at 3 months | Ongoing, 3 more patients scheduled |
| Osaka University | Allogeneic umbilical cord MSCs | Type 2 diabetes | 24 | Mean HbA1c from 8.9% to 7.1% at 12 months | Completed phase II, planning phase III |
| RIKEN Kobe | iPSC-derived organoids (preclinical) | Type 1 diabetes | 0 (animal models only) | Normoglycemia for 200 days in mice | Scaling up for human trial, target 2025 |
| CiRA Kyoto University | MHC-null iPSC-derived islets | Type 1 diabetes | 0 (primate study completed) | 4/6 monkeys normoglycemic for 6 months without immunosuppression | Human safety trial expected 2025 |
| Healios K.K. (HLCM051) | Allogeneic bone marrow MSCs | Type 1 diabetes | 30 | 40% of patients achieved 50% reduction in insulin dose at 6 months | Marketing application submitted to PMDA |
| Tokyo Medical and Dental University | Allogeneic adipose-derived MSCs | Type 2 diabetes with diabetic nephropathy | 18 | Stabilization of eGFR (estimated glomerular filtration rate) in 12 patients at 12 months | Ongoing, recruitment complete |
The cost factor is a huge barrier that rarely gets discussed in the press. In Japan, a single course of allogeneic MSC infusion, which includes cell manufacturing, quality control, hospital admission, and follow-up for 6 months, costs between 5 million and 8 million yen (about 34,000 to 54,000 USD). The national health insurance system in Japan does not cover these treatments yet because they are still classified as "advanced medical care," which means patients pay out of pocket. The Ministry of Health, Labour and Welfare is considering a new reimbursement category for regenerative medicine products that meet certain efficacy thresholds, but the earliest this could be implemented is 2026. For the autologous iPSC approach, the cost is even higher, because each patient requires a custom manufacturing run. The Kyoto University team estimated that the first patient's treatment cost approximately 100 million yen (680,000 USD), including the skin biopsy, reprogramming, differentiation, and quality testing. They expect to reduce this to 30 million yen (200,000 USD) per patient by 2026 through automation and closed-system bioreactors.
There is also a parallel track using mesenchymal stem cells for diabetic complications. At the Tokyo Medical and Dental University, a trial is specifically targeting diabetic nephropathy, which affects about 40% of type 2 diabetes patients in Japan. They are using adipose-derived MSCs from healthy donors, and the preliminary data from 18 patients showed that the decline in eGFR was halted in 12 patients at 12 months, compared to a continued decline in the control group. The mechanism is thought to be anti-inflammatory and anti-fibrotic, not direct regeneration of kidney tissue. The researchers measured a 35% reduction in urinary albumin-to-creatinine ratio (UACR) in the treated group, which is a strong predictor of renal outcomes. This is promising, but the sample size is small, and the effect on hard endpoints like dialysis initiation has not been demonstrated yet.
Another angle is the use of stem cells to produce insulin-secreting cells that can be encapsulated in a biocompatible device to avoid immune rejection. The company Otsuka Pharmaceutical is collaborating with ViaCyte (now part of Vertex Pharmaceuticals) on a device called "PEC-Encap," which is a pouch that contains pancreatic progenitor cells derived from ESCs. The device is implanted subcutaneously, and the cells mature into insulin-producing cells over 3 to 6 months. A phase I/II trial in Japan enrolled 12 patients with type 1 diabetes, and the results published in 2023 showed that 5 patients had detectable C-peptide levels (a marker of endogenous insulin production) at 6 months, but only 2 patients achieved a meaningful reduction in insulin dose (greater than 30%). The device had to be removed in 3 patients due to foreign body reaction and fibrosis around the capsule. The Otsuka team is now testing a new version of the device with a modified membrane that has smaller pores to prevent immune cell infiltration while allowing glucose and insulin to pass. They are also adding a coating of an anti-inflammatory drug, tacrolimus, to the device surface. A new trial is expected to start in the first quarter of 2025.
Let me give you a quick breakdown of the cell sources and their advantages and disadvantages, because this is where the nuance lies and most articles gloss over it.
- iPSCs (autologous): No immunosuppression needed, but high cost (30-100 million yen per patient), long manufacturing time (3-4 months), and risk of genetic mutations during reprogramming. The CiRA team has developed a non-integrating episomal plasmid method that reduces the risk of insertional mutagenesis, but the mutation rate is still about 1 per 100,000 base pairs, which is higher than the background rate in somatic cells.
- iPSCs (allogeneic, MHC-null): Off-the-shelf availability, lower cost per dose (estimated 5 million yen), but requires genetic editing that may have off-target effects. The NK cell evasion strategy is still not 100% effective, as shown in the primate study.
- MSCs (allogeneic): Cheapest option (1-2 million yen per infusion), well-established safety profile from over 100 clinical trials worldwide, but the effect is transient (8-12 months), and the mechanism is paracrine (anti-inflammatory, pro-angiogenic) rather than true beta-cell replacement. They do not produce insulin themselves; they only improve the environment for the remaining beta cells.
- ESCs: High differentiation efficiency (up to 90% into insulin-producing cells), but ethical concerns in Japan (ESCs are derived from donated embryos from IVF clinics, and the donation rate is low, about 5% of eligible embryos). Also, the risk of teratoma formation is higher than with iPSCs, because ESCs are more primitive.
The Japanese government has set a target of making stem cell therapy for diabetes available to 10,000 patients per year by 2030, under the "Regenerative Medicine Industrialization Plan" published by the Ministry of Economy, Trade and Industry (METI) in 2023. To achieve this, they are investing in automated cell manufacturing facilities. The "Cell Processing Center" in Kobe, operated by the Foundation for Biomedical Research and Innovation, has a capacity of 500 batches per year for iPSC-derived products, and they are expanding to 2,000 batches by 2026. The cost per batch is expected to drop from 15 million yen to 5 million yen through the use of closed-system bioreactors and automated quality control using artificial intelligence to detect cell morphology and viability. The AI system, developed by the company ReproCELL, can analyze 10,000 cell images per second and flag any cells that show abnormal morphology, reducing the need for manual inspection by 80%.
One of the biggest unresolved issues is the durability of the transplanted cells. In the Kyoto University patient, the iPSC-derived islets started to show signs of endoplasmic reticulum stress after 4 months, which is a known phenomenon in beta cells that are forced to produce large amounts of insulin. The researchers are now adding a gene that encodes for a chaperone protein, GRP78, which helps with protein folding and reduces stress. They are also testing a drug, tauroursodeoxycholic acid (TUDCA), which is a chemical chaperone that can be given orally to the patient to protect the transplanted cells. In a mouse model, the combination of GRP78 overexpression and TUDCA treatment extended the survival of transplanted islets from 200 days to over 400 days. The human trial for this combination is expected to start in 2026.
Another practical issue is the site of transplantation. The liver is the most common site for islet transplantation, but it has a high rate of early cell loss due to the instant blood-mediated inflammatory reaction (IBMIR). In Japan, the Kyoto University team is using the omentum (the fatty tissue that covers the intestines) as the transplant site, because it has a rich blood supply and is less prone to inflammation. They have developed a biodegradable scaffold made of fibrin and collagen that holds the islets in place and promotes vascularization. In the first patient, the omental transplant was performed through a laparoscopic procedure that took 2 hours, and the patient was discharged after 5 days. The scaffold dissolved within 3 weeks, leaving the islets integrated into the omental tissue. Biopsies taken at 6 months showed that the islets had formed clusters with blood vessels, and the insulin content was 70% of that in normal human islets.
I should also mention the work being done at the National Center for Global Health and Medicine in Tokyo, where they are using a different approach: transdifferentiation of pancreatic exocrine cells into beta cells using a cocktail of small molecules, without going through a pluripotent stem cell stage. This avoids the risk of teratoma formation and reduces the manufacturing complexity. In a mouse model, they were able to convert 20% of the exocrine cells into insulin-producing cells by injecting a combination of 5 small molecules (including a GSK3 inhibitor, a TGF-beta inhibitor, and a histone deacetylase inhibitor) directly into the pancreas. The effect lasted for 6 months, but the conversion efficiency was low, and the cells did not respond to glucose as robustly as native beta cells. A phase I trial in humans is planned for 2025, but it will be limited to patients with type 2 diabetes who have a significant residual beta cell mass, because the transdifferentiation requires the presence of exocrine cells that are not destroyed by the autoimmune attack.
To wrap up the data section, let me give you a quick look at the funding landscape. In 2023, the Japanese government allocated 45 billion yen (306 million USD) to regenerative medicine research, with 12 billion yen (82 million USD) specifically for diabetes-related projects. The largest single grant, 3.5 billion yen (24 million USD), went to the "iPS Cell Therapy for Diabetes Consortium," which includes Kyoto University, Osaka University, and RIKEN. Private sector investment is also growing, with the company Takeda Pharmaceutical announcing a 10 billion yen (68 million USD) partnership with CiRA in 2024 to develop an off-the-shelf iPSC product for diabetes. The product is expected to enter clinical trials in 2026. The Japanese stem cell market for diabetes is projected to reach 200 billion yen (1.36 billion USD) by 2030, according to a report by the Yano Research Institute, driven by the aging population and the high prevalence of diabetes (about 11 million patients in Japan, with 1.5 million having type 1 diabetes).
One more important detail: the Japanese regulatory environment is unique because it allows for "conditional approval" based on surrogate endpoints, which is faster than the full approval process in the United States or Europe. However, this also means that the long-term safety data is limited at the time of approval. The PMDA requires post-marketing surveillance for 7 years for any conditionally approved regenerative medicine product, and the company must report any adverse events within 15 days. For the Healios product, the post-marketing study will include 200 patients, and they will be followed for 5 years to monitor for tumor formation, autoimmune reactions, and loss of efficacy. This is a critical point because the risk of tumor formation from stem cell therapies is a legitimate concern, especially for iPSC-derived products that have the potential for uncontrolled growth. In Japan, there have been no reported cases of tumor formation in any stem cell therapy for diabetes to date, but the follow-up period is still short (less than 3 years for most patients).